Keyword Search
 
2017 | 2016 | 2015
  • Altimmune Announces Presentation at Biotech Showcase 2016
  • December 21, 2015 - Gaithersburg, Maryland – DEC. 21, 2015 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 – 13, 2016 in San Francisco, CA.Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Tuesday January 12, 2016 at 4:45 p.m. PST. The presentation will be held in the Hearst room of the Parc 55 Hotel.About Altimmune Altimmune is a clinical stage immunotherapeutic company foc... 
  • Altimmune Chief Scientific Officer to Present at Two Premier Vaccine Conferences
  • October 12, 2015 - Gaithersburg, Maryland – Oct. 12, 2015- Altimmune, Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two premier vaccine conferences in the coming weeks. The first is Bacillus ACT 2015, the international conference on Bacillus anthracis, B. ceres & B. thuringiensis, to be held later this month in New Delhi, India. The second is Vaccines R&D-2015, presented by the United Scien... 
  • Altimmune Ceo to Present at the 2015 Ladenburg Thalmann Healthcare Conference in New York City
  • September 28, 2015 - Gaithersburg, Maryland – Sept 28, 2015- Altimmune Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that CEO Bill Enright will present at the 2015 Ladenburg Thalmann Healthcare Conference to be held tomorrow at the Sofitel Hotel in New York City. Enright’s presentation will take place at 11:30am ET.For information on Ladenburg Thalmann, please visit www.ladenburg.com.About Altimmune Altimmune is a clinical stage biotechnology company developing next... 
  • Vaxin Changes Company Name to Altimmune
  • September 01, 2015 - Move Reflects Company’s Expansion beyond Vaccines to Include ImmunotherapeuticsGaithersburg, Maryland – Sept 1st 2015- Vaxin Inc., a clinical stage immunotherapy and vaccine company, today announced that it has changed its corporate name to Altimmune, Inc. Vaxin was founded in 1997 to pioneer new-generation vaccine technologies and products. Since then, the company has achieved steady success, developing promising vaccine candidates for biodefense and other public health needs, as well as animal... 
  • Vaxin First-in-Man Phase I Clinical Trial Initiated in Chronically Infected Hepatitis B Patients
  • July 27, 2015 - Gaithersburg, Maryland – July 27 2015- Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, today announced that it has enrolled the first patient into a phase I clinical trial of HepTcell™ (FP-02.2), the company’s immunotherapeutic compound to treat people chronically infected with the hepatitis B virus (HBV). The multicenter trial will be conducted at seven sites within the United Kingdom, and aims to recruit 72 patients with chronic HBV infection.The trial is a randomized, dou... 
  • Vaxin Strengthens Intellectual Property Portfolio
  • July 21, 2015 - Gaithersburg, Maryland – July 21 2015- Vaxin Inc. today announced that it has added key patents to its expanding Intellectual Property (IP) portfolio. The clinical stage vaccine and immunotherapeutics company confirmed that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two patents that protect important elements of its Densigen platform technology for immunotherapeutic treatment of Hepatitis B virus infection, and its RespirVec non-invasive adenoviral... 
  • Study Demonstrates Superior Performance of Vaxin’s Advav Vaccine for Protection against Aerosolized Anthrax
  • April 29, 2015 - Results Published in Clinical Vaccine Immunology Compares AdVAV FavorablyAgainst Only Currently Licensed AlternativeGaithersburg, MD – April 29, 2015 –Vaxin Inc., a clinical stage vaccine development company, today announced that a recently published study demonstrated that utilizing a single vaccination with the company’s AdVAV™ intranasal anthrax vaccine performs as well as the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax®), which requires two vaccinations. AdVAV is administered ... 
  • Vaxin Names Elizabeth Adkins Czerepak as Chief Financial Officer
  • April 13, 2015 - Gaithersburg, Md., April 13, 2015 —Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer (CFO). Vaxin develops vaccines for important public health and biodefense needs. Ms. Czerepak is a finance expert with over 20 years of executive experience in the pharmaceutical, biotech, and venture capital industries. As Vaxin’s CFO, she will grow the company’s finance organization, oversee M&A activities, and dri... 

    © 2017 Altimmune, Inc.   All rights reserved.   Terms of Use